Principal Financial Group’s Filana Therapeutics FLNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-10,965
Closed -$222K 2446
2024
Q1
$222K Buy
10,965
+355
+3% +$8.18K ﹤0.01% 2151
2023
Q4
$239K Buy
10,610
+56
+0.5% +$1.18K ﹤0.01% 2119
2023
Q3
$176K Sell
10,554
-223
-2% -$4.42K ﹤0.01% 2186
2023
Q2
$264K Buy
10,777
+777
+8% +$18.7K ﹤0.01% 2108
2023
Q1
$241K Sell
10,000
-754
-7% -$20.9K ﹤0.01% 2136
2022
Q4
$318K Buy
10,754
+573
+6% +$20.6K ﹤0.01% 2086
2022
Q3
$426K Sell
10,181
-229
-2% -$6.18K ﹤0.01% 1996
2022
Q2
$292K Sell
10,410
-90,948
-90% -$2.3M ﹤0.01% 2190
2022
Q1
$3.76M Sell
101,358
-44,180
-30% -$1.87M ﹤0.01% 1744
2021
Q4
$6.36M Buy
145,538
+16,172
+13% +$848K ﹤0.01% 1584
2021
Q3
$8.03M Buy
129,366
+2,876
+2% +$240K 0.01% 1509
2021
Q2
$10.8M Buy
126,490
+121,876
+2,641% +$6.53M 0.01% 1391
2021
Q1
$207K Buy
+4,614
New +$181K ﹤0.01% 2378
2015
Q1
Sell
-1,514
Closed -$22K 2199
2014
Q4
$22K Sell
1,514
-266
-15% -$4.61K ﹤0.01% 2167
2014
Q3
$49K Hold
1,780
﹤0.01% 2186
2014
Q2
$72K Buy
+1,780
New +$65.9K ﹤0.01% 2218

Other funds holding FLNA

Principal Financial Group's FLNA Position: Q2 2024 in Review

Principal Financial Group sold out of Filana Therapeutics (FLNA) in Q2 2024, closing a stake of 10,965 shares — an estimated $222K sold.

Principal Financial Group first reported a position in FLNA in Q2 2014 and held it in 16 quarters. The position peaked at $10.8M in Q2 2021. 145 funds tracked by Wall St. Rank hold FLNA as of Q2 2024.

  • Principal Financial Group reported no remaining Filana Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Principal Financial Group sold 10,965 Filana Therapeutics shares in Q2 2024, an estimated $222K.
  • Principal Financial Group first reported a position in Filana Therapeutics in Q2 2014 and held it in 16 quarters.
  • Principal Financial Group's Filana Therapeutics position peaked at $10.8M in Q2 2021.
  • 145 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2024.

Based on Principal Financial Group's 13F filing for Q2 2024, filed 29 Jul 2024.